Loading...

Louis VanderMolen, MD

Title(s)Professor of Clinical Medicine
Address520 Superior Avenue, Suite 300
Health Sciences Campus
Newport Beach CA 92663
Phone+1 323 226 7593
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Phi Beta Kappa1977Elected Member
    Baylor College of Medicine1983  - 1984Chief Resident, Internal Medicine
    Orange County Medical Association2006  - 2013Physician of Excellence Award

    Collapse Overview 
    Collapse Overview
    Dr. VanderMolen earned his medical degree from Loyola University Stritch School of Medicine. He performed his Internal Medicine Internship and Residency from Baylor College of Medicine- Texas Medical Center. He then went on to complete two fellowships, the first in hematology at Baylor, and the second in oncology at National Cancer Institute- Clinical Oncology Program.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012 Aug; 27(6):337-43. Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, McClure SE. PMID: 22804456.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    2. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm. 2011 Jun; 26(3):273-7. Dillman RO, Barth NM, VanderMolen LA, Fong WH, Mahdavi KK, McClure SE. PMID: 21711094.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer. Am J Otolaryngol. 2012 Jan-Feb; 33(1):93-7. Kim B, Dillman RO, Chen P, Hafer R, Cox C, Barth N, Carroll RM, VanderMolen L, Nguyen M, Huang J, Minion A, Plunkett M, Mackintosh R. PMID: 21524816.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants. Am J Clin Oncol. 2005 Jun; 28(3):281-8. Dillman RO, Barth NM, VanderMolen LA, Allen K, Beutel LD, Chico S. PMID: 15923802.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    5. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm. 2004 Oct; 19(5):570-80. Dillman R, Barth N, Vandermolen L, Mahdavi K, Beutel L, de Leon C, DePriest C, Nayak S. PMID: 15650449.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    6. Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr; 26(2):141-5. Dillman RO, O'Connor AA, Simpson L, Barth NM, VanderMolen LA, Vanderplas P. PMID: 12714884.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest. 2002; 20(2):206-7. VanderMolen LA, Sheehy PF, Dillman RO. PMID: 11901541.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm. 2001 Feb; 16(1):47-54. Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK. PMID: 11279797.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    9. Profile of the pediatric endocrine clinic at New York-Presbyterian Hospital, New York Weill Cornell Center. J Clin Endocrinol Metab. 1999 Dec; 84(12):4444-9. New MI, Obeid J, Wilson RC, Cabrera MS, Goseco A, Macapagal MC, Marshall I, Nimkarn S, Quintos JB, Ten S, Ugrasbul F, Vandermolen L, Harbison MD. PMID: 10599700.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm. 1997 Aug; 12(4):249-55. Dillman RO, Wiemann MC, VanderMolen LA, Bury MJ, DePriest C, Church C. PMID: 10851472.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    11. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. J Clin Oncol. 1996 Aug; 14(8):2234-41. Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL. PMID: 8708712.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    12. Malignant melanoma and pregnancy ten questions. West J Med. 1996 Feb; 164(2):156-61. Dillman RO, Vandermolen LA, Barth NM, Bransford KJ. PMID: 8775729.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    13. The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center. Cancer Biother. 1995; 10(1):25-36. Dillman RO, Barth NM, Mahdavi K, VanderMolen LA, Nayak SK, O'Connor A. PMID: 7780484.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol. 1993 Nov; 11(11):2118-26. Reed E, Janik J, Bookman MA, Rothenberg M, Smith J, Young RC, Ozols RF, VanderMolen L, Kohn E, Jacob JL. PMID: 8229126.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    15. Primary lymphoma of the kidney: complete remission after systemic chemotherapy. J Natl Cancer Inst. 1993 Mar 17; 85(6):505-6. Vandermolen LA, Dillman RO. PMID: 8445680.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst. 1992 Jun 17; 84(12):929-37. Sznol M, Clark JW, Smith JW, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG. PMID: 1629914.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    17. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol. 1990 Oct; 8(10):1618-29. Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE. PMID: 2213099.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    18. Surface light chain phenotype in indolent lymphomas: lack of prognostic significance. Am J Hematol. 1990 May; 34(1):15-20. VanderMolen LA, Duffey PL, Cossman J, Jaffe ES, Longo DL. PMID: 2109529.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Erythrocytosis in hairy cell leukaemia following therapy with interferon alpha. Br J Haematol. 1990 May; 75(1):133-5. Steis RG, VanderMolen LA, Lawrence J, Sing G, Ruscetti F, Smith JW, Urba WJ, Clark J, Longo DL. PMID: 2375913.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst. 1990 Apr 18; 82(8):697-703. Steis RG, VanderMolen LA, Longo DL, Clark JW, Smith JW, Kopp WC, Ruscetti FW, Creekmore SP, Elwood LJ, Hursey J. PMID: 2138680.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    21. Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):235-8. VanderMolen LA, Steis RG, Duffey PL, Foon KA, Smith JW, Clark JW, Conlon K, Stevenson HC, Urba WJ, Hartmann LC. PMID: 2296053.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    22. Diffuse osteosclerosis in hairy cell leukemia. Blood. 1989 Nov 01; 74(6):2066-9. VanderMolen LA, Urba WJ, Longo DL, Lawrence J, Gralnick H, Steis RG. PMID: 2804348.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    23. Adrenal insufficiency and interleukin-2 therapy. Ann Intern Med. 1989 Jul 15; 111(2):185. VanderMolen LA, Smith JW, Longo DL, Steis RG, Kremers P, Sznol M. PMID: 2787137.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Hypothyroidism after interleukin-2 therapy. J Clin Oncol. 1989 May; 7(5):686-7. Hartmann LC, Urba WJ, Steis RG, Smith JW, VanderMolen L, Creekmore SP, Longo DL. PMID: 2785167.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Lactic acidosis in lymphoma: prompt resolution of acidosis with therapy directed at the lymphoma. J Natl Cancer Inst. 1988 Sep 07; 80(13):1077-8. VanderMolen LA, Swain S, Longo DL. PMID: 3411621.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors. Arch Intern Med. 1988 Mar; 148(3):653-6. Vandermolen L, Rice L, Rose MA, Lynch EC. PMID: 3341866.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Torsade de pointes: an unusual manifestation of chloral hydrate poisoning. Am Heart J. 1986 Jul; 112(1):181-4. Young JB, Vandermolen LA, Pratt CM. PMID: 3728278.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome. Am J Med. 1985 Sep; 79(3):297-302. Vandermolen L, Rice L, Lynch EC. PMID: 4036981.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Multiple myeloma in a homosexual man with chronic lymphadenopathy. Arch Intern Med. 1985 Apr; 145(4):745-6. Vandermolen LA, Fehir KM, Rice L. PMID: 3920986.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Louis's Networks
    Concepts (170)
    Derived automatically from this person's publications.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _